Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 493-500

  Dolton, Michael J ^a,b   McLachlan, Andrew J ^b,c  

^a University of Southern California   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Geriatric Medicine   (Australia)

Author keywords

Azole antifungal agents; Dose individualization; Exposure response; Therapeutic drug monitoring

Indexed keywords

ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG MONITORING; FEASIBILITY STUDY; HUMAN; INFECTION PREVENTION; MYCOSIS; PERSONALIZED MEDICINE; REVIEW; TREATMENT OUTCOME; URINARY EXCRETION; ANTIBIOTIC PROPHYLAXIS; DOSE RESPONSE; HEALTH SURVEY; IMMUNOLOGY; MICROBIOLOGY; MYCOSES;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; ITRACONAZOLE; MYCOSES; POPULATION SURVEILLANCE; TRIAZOLES; VORICONAZOLE;

EID: 84927796421     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000103     Document Type: Review

References (116)

1. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004; 10 (Suppl 1):1-10.
2. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30:653-657.
3. Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56:5503-5510.
4. Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:4793-4799.
5. Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol 2013; 9:911-926.
6. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (Suppl 1):i17-i22.
7. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-966.
8. Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother 2014; 69:1633-1641.
9. Andes D, Dismukes W. Azoles. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. New York: Springer; 2011. pp. 61-93.
10. Luong M-L, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12:1929-1935.
11. Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-1458.
12. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl 3):S318-S326.
13. Csajka C, Décosterd L, Buclin T, et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001; 57:723-727.
14. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother 1995; 39:1835-1841.
15. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162-1176.
16. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/07/news-detail-001855.jsp&mid=WC0b01ac058004d5c1. [Accessed 5 May 2014]
17. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm. [Accessed 5 May 2014]
18. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807-825.
19. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801-1812.
20. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
21. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990; 112:108-112.
22. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33:e83-e90.
23. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32:1310-1313.
24. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54:159-161.
25. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42:1862-1865.
26. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37:778-784.
27. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998; 18:295-301.
28. Conte JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob Agents Chemother 2004; 48:3823-3827.
29. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58:617-624.
30. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994; 38:1561-1566.
31. Wiederhold NP, Pennick GJ, Dorsey SA, et al. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother 2014; 58:424-431.
32. Heykants J, van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 (Suppl 1):67-87.
33. Mikami Y, Sakamoto T, Yazawa K, et al. Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay. Mycoses 1994; 37:27-33.
34. Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000; 45:371-373.
35. Odds FC, Dupont B, Rinaldi MG, et al. Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother 1999; 43:723-727.
36. Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37:2224-2227.
37. Kunze KL, Nelson WL, Kharasch ED, et al. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006; 34:583-590.
38. Shi W, Nacev BA, Bhat S, Liu JO. Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole. ACS Med Chem Lett 2010; 1:155-159.
39. Pyrgaki C, Bannister SJ, Gera L, et al. Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection. Chirality 2011; 23:495-503.
40. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 (Suppl 1):103-108.
41. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42:443-451.
42. Glasmacher A, Prentice A, Gorschlü ter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21:4615-4626.
43. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97:135-144.
44. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49:928-930.
45. Lestner JM, Denning DW. Tremor: a newly described adverse event with long-term itraconazole therapy. J Neurol Neurosurg Psychiatry 2010; 81:327-329.
46. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
47. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis2003;36:1122-1131.
48. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008-3016.
49. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-456.
50. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag 2007; 3:1165-1173.
51. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-637.
52. Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013; 13:105.
53. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16:927-933.
54. Racil Z, Winterova J, Kouba M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 2012; 55:483-492.
55. Geist MJP, Egerer G, Burhenne J, et al. Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother 2013; 68:2592-2599.
56. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571.
57. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211.
58. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89:592-599.
59. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546-2553.
60. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31:540-547.
61. Sim SC, Risinger C, Dahl M-L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79:103-113.
62. Uppugunduri CRS, Daali Y, Desmeules J, et al. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab 2012; 13:1196-1204.
63. Lee S, Kim B-H, Nam W-S, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2013; 52:195-203.
64. Scholz I, Oberwittler H, Riedel K-D, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68:906-915.
65. Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-termvoriconazole therapy. Clin Infect Dis 2011; 52:604-611.
66. Thompson GR, Bays D, Cohen SH, Pappagianis D. Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles. Antimicrob Agents Chemother 2012; 56:563-564.
67. Gerber B, Guggenberger R, Fasler D, et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 2012; 120:2390-2394.
68. Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014; 58:997-1002.
69. Centers for Disease Control and Prevention. CDC fungal meningitis outbreak case count. http://www.cdc.gov/hai/outbreaks/meningitis-map-large.html. [Accessed 2 July 2014]
70. Malani AN, Kerr L, Obear J, et al. Alopecia and nail changes associated with voriconazole therapy. Clin Infect Dis 2014; 59:e61-e65.
71. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243.
72. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55:4782-4788.
73. Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical metaanalysis. J Infect Chemother 2012; 18:501-507.
74. Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55:381-390.
75. Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: Assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents 2014; 44:183-193.
76. Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis 2014; 209:1941-1948.
77. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012; 56:3032-3042.
78. Hope WW. Population pharmacokinetics of voriconazole in adults. Antimicrob Agents Chemother 2012; 56:526-531.
79. Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet 2011; 50:201-214.
80. Hope WW, VanGuilder M, Donnelly JP, et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother 2013; 57:1888-1894.
81. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22:447-467.
82. Wong C, Kumar SS, Graham GG, et al. Comparing dose prediction software used to manage gentamicin dosing. Intern Med J 2013; 43:519-525.
83. Wright DB, Duffull S. A Bayesian dose-individualization method for warfarin. Clin Pharmacokinet 2013; 52:59-68.
84. Benkali K, Prémaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48:805-816.
85. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359.
86. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347.
87. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-1403.
88. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
89. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775-785.
90. Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2014; 33:629-638.
91. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:2806-2813.
92. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211-220.
93. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88:115-119.
94. Thompson GR, Rinaldi MG, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009; 53:2223-2224.
95. Bryant AM, Slain D, Cumpston A, Craig M. A postmarketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011; 37:266-269.
96. Ray J, Campbell L, Rudham S, et al. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit 2011; 33:387-392.
97. Eiden C, Meniane JC, Peyriè re H, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012; 31:161-167.
98. Hoenigl M, Raggam RB, Salzer HJF, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39:510-513.
99. European Medicines Agency. Noxafil: EPAR-production information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000610/WC500037784.pdf. [Accessed 2 June 2014]
100. U.S. Food and Drug Administration. Posaconazole tablet approved prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205053s000lbl.pdf. [Accessed 2 June 2014]
101. Kraft WK, Chang PS, van Iersel MLPS, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014; 58:4020-4025.
102. Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56:4196-4201.
103. European Medicines Agency. Noxafil: EPAR-assessment report. 20 February 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000610/WC500168187.pdf. [Accessed 4 July 2014]
104. Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single-and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 2012; 67:2725-2730.
105. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788-2795.
106. Cojutti P, Candoni A, Simeone E, et al. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother 2013; 57:6081-6084.
107. Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014; 58:3610-3617.
108. Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28:1223-1232.
109. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627-1636.
110. Vehreschild JJ, Mü ller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 2012; 68:987-995.
111. Ostrosky-Zeichner L, Casadevall A, Galgiani J, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9:719-727.
112. Basilea Pharmaceutica. Basilea reports positive topline phase 3 results for antifungal isavuconazole. 2013 [cited 12 Nov 2013]. http://www.basilea.com/News-and-Media/Basilea-reports-positive-topline-phase-3-results-forantifungal-isavuconazole/967f3c8d-ab30-eb6c-ca6a-da36b215e20d.
113. National Institute of Mental Health; University of Virginia. Isavuconazole (BAL8557) in the treatment of candidemia and other invasive Candida infections. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 15 June 2014]. http://clinicaltrials.gov/show/NCT00413218 NLM Identifier: NCT00413218.
114. Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.
115. Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012; 8:759-765.
116. Schmitt-Hoffman, Roos B, Sauer J. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral daily doses of BAL8557 (WSA) and rifampicin. In: 16th Congress of the International Society of Human and Animal Mycology; 2006; Paris, France.